Mowry E M, Loguidice M J, Daniels A B, Jacobs D A, Markowitz C E, Galetta S L, Nano-Schiavi M L, Cutter G R, Maguire M G, Balcer L J
Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
J Neurol Neurosurg Psychiatry. 2009 Jul;80(7):767-72. doi: 10.1136/jnnp.2008.165449. Epub 2009 Feb 23.
To examine the relation between low contrast letter acuity, a new visual function test for multiple sclerosis (MS) trials, and vision targeted health related quality of life (HRQOL).
Patients in this cross sectional study were part of an ongoing investigation of visual function in MS. Patients were tested binocularly using low contrast letter acuity and Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) charts. The 25 Item National Eye Institute Visual Functioning Questionnaire (NEI-VFQ-25), 10 Item Neuro-Ophthalmic Supplement to the NEI-VFQ-25, Impact of Visual Impairment Scale and Short Form 36 Health Survey (SF-36) were administered.
Among 167 patients, mean age was 48 (10) years, with median Expanded Disability Status Scale (EDSS) 2.0 (range 1.0-7.5), and median binocular Snellen acuity equivalent (ETDRS charts) 20/16 (range 20/12.5 to 20/100). Reductions in vision specific HRQOL were associated with lower (worse) scores for low contrast letter acuity and VA (p<0.001, linear regression, accounting for age). Two line differences in visual function were associated, on average, with >4 point (6.7-10.9 point) worsening in the NEI-VFQ-25 composite score, reductions that are considered clinically meaningful. Scores for the 10 Item Neuro-Ophthalmic Supplement to the NEI-VFQ-25 also correlated well with visual function. Associations between reduced low contrast acuity and worse vision targeted HRQOL remained significant in models accounting for high contrast VA, EDSS and history of acute optic neuritis.
Low contrast letter acuity scores correlate well with HRQOL in MS. Two line differences in scores for low contrast acuity and VA reflect clinically meaningful differences in vision targeted HRQOL. Low contrast acuity testing provides information on patient reported aspects of vision, supporting use of these measures in MS clinical trials.
研究低对比度字母视力(一种用于多发性硬化症(MS)试验的新视觉功能测试)与以视力为目标的健康相关生活质量(HRQOL)之间的关系。
本横断面研究中的患者是正在进行的MS视觉功能调查的一部分。使用低对比度字母视力表和早期糖尿病视网膜病变研究(ETDRS)视力(VA)表对患者进行双眼测试。发放了25项美国国立眼科研究所视觉功能问卷(NEI-VFQ-25)、NEI-VFQ-25的10项神经眼科补充问卷、视觉障碍影响量表和简明健康调查(SF-36)。
167例患者中,平均年龄为48(10)岁,扩展残疾状态量表(EDSS)中位数为2.0(范围1.0 - 7.5),双眼Snellen视力等效值(ETDRS视力表)中位数为20/16(范围20/12.5至20/100)。视力特异性HRQOL的降低与低对比度字母视力和VA的较低(较差)得分相关(p<0.001,线性回归,校正年龄因素)。视觉功能上两行的差异平均与NEI-VFQ-25综合得分恶化>4分(6.7 - 10.9分)相关,这种降低被认为具有临床意义。NEI-VFQ-25的10项神经眼科补充问卷得分也与视觉功能密切相关。在考虑高对比度VA、EDSS和急性视神经炎病史的模型中,低对比度视力降低与较差的以视力为目标的HRQOL之间的关联仍然显著。
低对比度字母视力得分与MS患者的HRQOL密切相关。低对比度视力和VA得分两行的差异反映了以视力为目标的HRQOL在临床上的有意义差异。低对比度视力测试提供了患者报告的视力方面的信息,支持在MS临床试验中使用这些测量方法。